The Asia-Pacific Dengue Prevention Board organized a meeting (Kuala Lumpur, Malaysia, 1–2 June 2016) to highlight points for consideration about CYD-TDV vaccine introduction and to define the most useful tools and approaches for dengue endemic countries to develop policies.
We invite you to read the full report on the "Development of Dengue Vaccines: Issues relating to dengue vaccine introduction in light of the WHO SAGE recommendations" here.
There has been an explosive increase in dengue cases in recent years. The disease has a substantial impact on individuals and society, including lost wages, decreased productivity and costs associated with seeking and obtaining care, yet no drugs are available to prevent or treat dengue infection.
As the range and severity of dengue grows, so too does the need for more effective methods of prevention, and for a better understanding of the scope and cost of the problem. Substantial progress towards finding a vaccine has been made in the last decade, and several vaccines are in various stages of advanced development. Historically, vaccines have taken twenty years or more to reach markets in the developing world; with a dengue vaccine the goal is to reduce the time before countries are able to review the necessary data and have the ability to introduce the vaccine if they decide to do so.
DVI is working on a number of fronts, outlined under What We Do, to lay the groundwork so that, once licensed, a dengue vaccine can be swiftly considered for adoption. This work includes gathering evidence on the impact of dengue through disease burden and cost of illness studies as well as modeling the impact of immunization developing Points for Consideration, financing strategies, and strategic demand forecasts.